Context:

A study of older Swedish women links lifetime estrogen exposure to better brain vessel health later in life. At age 70, past use of menopausal hormone therapy correlated with fewer signs of small-vessel damage in the brain, and shared a pattern with birth control use and a longer reproductive span. While findings suggest hormonal history may influence neurovascular aging, researchers caution that the study is observational and not proof that hormone therapy protects cognition. Experts stress that hormone therapy should not be used solely for brain benefits and must be tailored to individual risk factors and symptoms. Further long-term research is needed to clarify causality and optimal use.

Dive Deeper:

• The investigation followed about 350 community-dwelling women in Gothenburg, Sweden, all aged 70 and without memory problems at the start, with 205 undergoing a second MRI five years later to assess brain vessels.

• Researchers evaluated four imaging markers of cerebral small vessel disease: bright spots in white matter, small areas of prior strokes, microbleeds, and enlarged perivascular spaces, finding that roughly 40% displayed at least one sign.

• After adjusting for education, hypertension, diabetes, and other factors, women who had used menopausal hormone therapy showed about 59% lower odds of possessing two or more signs of small-vessel disease compared with non-users.

• Using both hormonal contraception earlier in life and menopausal hormone therapy was linked to the best-preserved white matter, with about 69% lower odds of two or more signs of small-vessel disease versus those who used neither.

• Later menopause (more years between first period and menopause) was associated with less brain vessel damage at age 70, though the effect was weaker than that for hormone therapy; age at first period did not show a clear impact.

• The study did not find a strong link between estrogen exposure and thinning in brain regions typically affected by Alzheimer's disease, except possibly among APOE-e4 carriers who used hormone therapy.

• Limitations include a relatively small, homogenous sample, reliance on self-reported hormone use (type, dose, timing often unknown), and the observational design which cannot establish causality or rule out healthy-user bias.